The MAX Study: A Randomised Phase II/III Study to Evaluate the Role of Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer

Trial Profile

The MAX Study: A Randomised Phase II/III Study to Evaluate the Role of Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer

Completed
Phase of Trial: Phase II/III

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Mitomycin
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MAX
  • Most Recent Events

    • 20 Jan 2018 Results (n=145) assessing the prognostic impact of single nucleotide polymorphisms variants (COL4A2, PPP1R17 and ARHGAPP44) and predictive effect on bevacizumab in patients from this trial, presented at the 2018 Gastrointestinal Cancers Symposium.
    • 03 Jun 2014 Results of the predictive/prognostic impact of SNP genotype presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 30 May 2014 Results on predictive impact of gene mutation status presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top